• About Us
    • Board of Directors
    • Advisors
    • Committees
    • Staff
  • Our Work
    • In The News
    • Newsletter Archive
  • Programs
    • Scholarship Program
  • Join Now
    • Veterinary Professional
    • Pet Parents
    • Product Industry
    • Login
  • Directory of Practitioners
  • Get Involved
    • Make A Donation
    • Become A Corporate Sponsor
    • Join Email List
  • Contact
  • DONATE
  • Members Dashboard
Veterinary Cannabis SocietyVeterinary Cannabis Society
  • About Us
    • Board of Directors
    • Advisors
    • Committees
    • Staff
  • Our Work
    • In The News
    • Newsletter Archive
  • Programs
    • Scholarship Program
  • Join Now
    • Veterinary Professional
    • Pet Parents
    • Product Industry
    • Login
  • Directory of Practitioners
  • Get Involved
    • Make A Donation
    • Become A Corporate Sponsor
    • Join Email List
  • Contact
  • DONATE
  • Members Dashboard

The interplay between first-pass effect and lymphatic absorption of cannabidiol and its implications for cannabidiol oral formulations

Home The interplay between first-pass effect and lymphatic absorption of cannabidiol and its implications for cannabidiol oral formulations

Curated Research Library

  • Back to Curated Research Library

The interplay between first-pass effect and lymphatic absorption of cannabidiol and its implications for cannabidiol oral formulations

  • By: Bialer, M., Franco, V., Gerchkovich, P., & Perucca, E
  • Published On: 12 August, 2020
  • Publication: link.springer.com
  • Tags: general, receptors
  • Category: Pharmacokinetics / Pharmacodynamics

For highly lipophilic drugs, passage into the intestinal lymphatic system rather than the portal vein following oral administration may represent a major alternative route of delivery into the general circulation. Increasing intestinal lymphatic transport provides an effective strategy to improve oral bioavailability when hepatic first-pass metabolism is a major rate-limiting step hampering access to the systemic circulation after oral dosing. The transfer of orally administered, highly lipid-soluble drugs to the lymphatic system is mediated by their association with chylomicrons, large intestinal lipoproteins that are assembled in the enterocytes in the presence of long-chain triglycerides or long-chain fatty acids. Due to its very high lipophilicity, cannabidiol (CBD) has physicochemical features (e.g. logP = 6.3) consistent with an oral absorption mediated at least in part by transport via the intestinal lymphatic system. CBD also undergoes extensive first-pass hepatic metabolism. Formulation changes favoring diversion of orally absorbed CBD from the portal to the lymphatic circulation pathway can result in reduced first-pass liver metabolism, enhanced oral bioavailability, and reduced intra- and intersubject variability in systemic exposure. In this manuscript, we discuss (1) evidence for CBD undergoing hepatic first-pass liver metabolism and lymphatic absorption to a clinically important extent; (2) the potential interplay between improved oral absorption, diversion of orally absorbed drug to the lymphatic system, and magnitude of presystemic elimination in the liver; and (3) strategies by which innovative chemical and/or pharmaceutical delivery systems of CBD with improved bioavailability could be developed.

Click Here to Access Article
  • Back to Curated Research Library
Search

Our Mission is to create lasting solutions that ensure the safe use of cannabis in pets through education, advocacy, and promoting product standards.

Our Vision is an educated and empowered global veterinary medical cannabis community.

  • About Us
  • Our Work
  • Members Area
  • Get Involved
  • Contact Us
  • Donate

Email:
Click here to email us

Florida Mailing Address
7901 4th St. North, Suite 4404
St. Petersburg, FL 33702

California Mailing Address
4382 Piedmont Avenue
Oakland, CA 94611

Veterinary Cannabis Society is a nonprofit, 501(c)(3) organization in the United States. Tax ID #85-0986090

Veterinary Cannabis Society does not endorse any specific products.

© 2023 · Veterinary Cannabis Society

  • Terms of Use
  • Privacy Policy
  • State Notices
  • Contact